FCNTX Mutual Fund Forecast & Price Targets

See the Price Targets and Ratings of:

FCNTX Analyst Rating

Moderate Buy
305ConsensusRatings
260 Buy
44 Hold
1 Sell
Based on the consensus analyst ratings on 305 stocks held in FCNTX.
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

FCNTX Analyst Price Target

Average Price Target

$23.96
Based on 305 Wall Street analysts offering 12 month price targets to Fidelity Contra Fund holdings in the last 3 months. The average price target is $23.96 with a high forecast of $27.89 and a low forecast of $19.72. The average price target represents a 12.21% change from the last price of $21.35.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"$13","28":"$28","16.75":"$16.75","20.5":"$20.5","24.25":"$24.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":27.885,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$27.89</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.957,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$23.96</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.72,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$19.72</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,16.75,20.5,24.25,28],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2024","6":"May<br/>2024","9":"Aug<br/>2024","12":"Nov<br/>2024","25":"Nov<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n              \n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.16,21.677307692307693,22.194615384615386,22.711923076923078,23.22923076923077,23.746538461538464,24.263846153846156,24.78115384615385,25.298461538461538,25.815769230769234,26.333076923076923,26.850384615384616,27.36769230769231,{"y":27.885,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.16,21.375153846153847,21.590307692307693,21.80546153846154,22.020615384615386,22.235769230769233,22.450923076923075,22.666076923076922,22.88123076923077,23.096384615384615,23.31153846153846,23.526692307692308,23.741846153846154,{"y":23.957,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.16,21.049230769230768,20.93846153846154,20.827692307692306,20.716923076923077,20.606153846153845,20.495384615384616,20.384615384615383,20.273846153846154,20.163076923076922,20.052307692307693,19.94153846153846,19.830769230769228,{"y":19.72,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.99,"date":1698796800000,"info":"<div>Price: <b>$15<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":15.99,"date":1701388800000,"info":"<div>Price: <b>$16<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":15.95,"date":1704153600000,"info":"<div>Price: <b>$16<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":17.08,"date":1706745600000,"info":"<div>Price: <b>$17<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":18.66,"date":1709251200000,"info":"<div>Price: <b>$19<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":19,"date":1711929600000,"info":"<div>Price: <b>$19<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":18.11,"date":1714521600000,"info":"<div>Price: <b>$18<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":19.47,"date":1717372800000,"info":"<div>Price: <b>$19<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":20.28,"date":1719792000000,"info":"<div>Price: <b>$20<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":19.71,"date":1722470400000,"info":"<div>Price: <b>$20<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":20.13,"date":1725321600000,"info":"<div>Price: <b>$20<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":20.96,"date":1727740800000,"info":"<div>Price: <b>$21<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":21.16,"date":1730419200000,"info":"<div>Price: <b>$21<b/></div>","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$27.89Average Price Target$23.96Lowest Price Target$19.72
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

FCNTX Stocks With Highest Upside Potential

Name
Price & Change
Analyst Consensus
Analyst Price Target
xxxxxxxxxxxxxxxxxxxxxxxxxxx
Celldex Therapeutics
9 Buy
2 Hold
0 Sell
Strong Buy
$65.70
xxxxxxxxxxxxxxxxxxxxxxxxxxx
Moderna
7 Buy
9 Hold
2 Sell
Moderate Buy
$97.62
xxxxxxxxxxxxxxxxxxxxxxxxxxx
Viking Therapeutics
11 Buy
0 Hold
0 Sell
Strong Buy
$113.67
xxxxxxxxxxxxxxxxxxxxxxxxxxx
Dyne Therapeutics, Inc.
7 Buy
1 Hold
0 Sell
Strong Buy
$50.00
xxxxxxxxxxxxxxxxxxxxxxxxxxx
Royalty Pharma PLC
5 Buy
0 Hold
0 Sell
Strong Buy
$44.40

FCNTX Stocks With Highest Downside Potential

Name
Price & Change
Analyst Consensus
Analyst Price Target
xxxxxxxxxxxxxxxxxxxxxxxxxxx
Aurora Innovation, Inc.
1 Buy
2 Hold
1 Sell
Hold
$4.63
xxxxxxxxxxxxxxxxxxxxxxxxxxx
Old Dominion Freight Line
3 Buy
10 Hold
2 Sell
Hold
$191.14
xxxxxxxxxxxxxxxxxxxxxxxxxxx
Centuri Holdings, Inc.
0 Buy
0 Hold
1 Sell
Moderate Sell
$16.00
xxxxxxxxxxxxxxxxxxxxxxxxxxx
Duolingo, Inc. Class A
8 Buy
4 Hold
0 Sell
Moderate Buy
$275.22
xxxxxxxxxxxxxxxxxxxxxxxxxxx
Reddit, Inc. Class A
10 Buy
5 Hold
1 Sell
Moderate Buy
$104.69

FCNTX Mutual Fund FAQ

What is FCNTX’s average 12-month price target, according to analysts?
Based on analyst ratings, Fidelity Contra Fund’s 12-month average price target is $23.96.
    What is FCNTX’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for FCNTX, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is FCNTX a Buy, Sell or Hold?
        Fidelity Contra Fund has a consensus rating of Moderate Buy which is based on 260 buy ratings, 44 hold ratings and 1 sell ratings.
          What is Fidelity Contra Fund’s price target?
          The average price target for Fidelity Contra Fund is $23.96. This is based on 305 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst price target is $27.89 ,the lowest forecast is $19.72. The average price target represents N/A Increase from the current price of N/A.
            What do analysts say about Fidelity Contra Fund?
            Fidelity Contra Fund’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 305 Wall Streets Analysts.
              How can I buy shares of FCNTX?
              Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis